Clever Leaves (NASDAQ:CLVR), Inc. (NASDAQ: CLVR) is a vertically integrated cannabis company specializing in the cultivation, extraction and distribution of pharmaceutical-grade medical cannabis. With production facilities strategically located in Colombia and Portugal, the company leverages favorable climates and stringent Good Manufacturing Practice (GMP) standards to produce a range of cannabinoid formulations for global markets. Its product portfolio includes dried flower, purified cannabinoids and custom formulations designed to meet regulatory requirements in key jurisdictions.
Originally founded in 2019, Clever Leaves completed a business combination with a special purpose acquisition company in 2021, resulting in its Nasdaq listing. Since then, the company has scaled its operations through the development of advanced cultivation technologies, tissue-culture propagation techniques and a state-of-the-art extraction facility in Portugal. Clever Leaves is focused on quality assurance, analytical testing and traceability protocols to support its mission of providing consistent, research-driven cannabis products.
Clever Leaves serves diverse markets across Europe, Latin America and Canada, supplying medical cannabis to patients and pharmaceutical partners. The company holds cultivation, manufacturing and distribution licenses in Colombia and Portugal, and it actively pursues product registrations and import approvals in regulated jurisdictions. Through collaborations with local clinical research organizations and strategic off-take agreements, Clever Leaves is working to expand patient access to cannabinoid-based therapies.
Guided by an experienced management team with backgrounds in agriculture, pharmaceutical manufacturing and international distribution, Clever Leaves seeks to establish itself as a global leader in the cannabis industry. By combining best-in-class cultivation practices, quality compliance and scientific research, the company aims to deliver scalable solutions that address evolving patient needs and regulatory landscapes.
